snehalshaha119@gmail.com snehal@119

[email protected] [email protected]

  • Northbrook

I am working as Research Analyst @ MNM Research

Followers 23
Following 95
The growth of this market is mainly driven by the growing focus on developing alternatives for animal testing models, significant increase in research funding and venture capital investments for the development of organs-on-chips, technological advancements and products launches, growing number of partnerships and collaborations between pharmaceutical companies and organs-on-chips manufacturers, and growing need for early detection of drug toxicity to minimize financial losses due to late stage drug failure.The Organs-on-chips Market  is expected to reach USD 45.6 million by 2022 from USD 9.6 million in 2017, at a CAGR of 36.6%.Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144117291Market Segmentation: -Based on type, the organs-on-chips market is segmented into liver, lung, heart, kidney, and other organs-on-chips.In 2017, the accessories segment is expected to account for the largest share of the organs-on-chips market.The large share of this segment can be attributed to the simplicity of this model and the ability of on-chip hepatic tissues to maintain metabolic activity and phenotype similar to the in vivo environment.Based on application, the organs-on-chips market is segmented into physiological model development, drug discovery, and toxicology research.The drug discovery segment is expected to register the highest CAGR during the forecast period.The increasing focus on drug discovery, rising need for more predictive in vitro tools for drug development among pharmaceutical companies, and growing preference for alternatives to conventional cell culture and animal models are some of the factors that are driving the growth of the drug discovery segment.Key Market Drivers :- 1 Growing Focus on Developing Alternatives for Animal Testing Models 2 Significant Increase in Research Funding and Venture Capital Investments for the Development of Organs-on-Chips 3 Technological Advancements and New Products Launches 4 Growing Number of Partnerships and Collaborations Between Pharmaceutical Companies and Organs-on-Chips Manufacturers 5 Growing Need for Early Detection of Drug Toxicity to Minimize Financial Losses Due to Late Stage Drug Failure 6 Growing Initiatives to Increase Awareness About Organs-on-Chips TechnologiesRegional Analysis: -In 2017, North America is expected to dominate the market followed by Europe.The large share of this geographical segment is attributed to factors such as availability of new and advanced organs-on-chips in the market.Request for Sample Pages  - https://www.marketsandmarkets.com/requestsampleNew.asp?id=144117291  Top key Players:-The organs-on-chips market is emerging and high growth potential market with the presence of several small players and startups firms.
Growing safety concerns post the Fukushima disaster, growing security threats, growing security budgets of global sporting events, increasing incidence of cancer, growth in the number of PET/CT scans, and growing threat of nuclear terrorism are expected to drive the growth of the global inorganic scintillators market in the coming years.The global inorganic scintillators market is segmented on the basis of scintillation material, type, application, and region.The report Inorganic Scintillators Market is expected to reach USD 330.7 Million by 2021 from USD 256.1 Million in 2016, growing at a CAGR of 5.2%.Ask For PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121799348                               By scintillation material, the inorganic scintillators market is categorized into Sodium Iodide (NaI), Cesium Iodide (CsI), Lutetium Oxyorthosilicate (LSO) and Lutetium-yttrium Oxyorthosilicate (LYSO), Bismuth Germanate Oxide (BGO), Others [Barium Fluoride (BaF2), Lead Tungstate (PbWO4), Cadmium Tungstate (CdWO4), Cerium Bromide (CeBr3), Lanthanum Bromide (LaBr3), and Gadolinium Orthosilicate (GSO)].The sodium iodide (NaI) segment is expected to command the largest share of the global inorganic scintillators market, by scintillation material in 2016.This is attributed to factors such as rising application horizon of sodium iodide, rise in homeland security expenditure to combat terrorism worldwide, and increasing number of nuclear power plants.On the basis of type, the global inorganic scintillators market is segmented into alkali halides, oxide compounds, and rare earth halides.The alkali halides segment is expected to account for the largest share of the global inorganic scintillators market in 2016.This can be attributed to the rising application horizon of alkali halides, increase in the research activities for space exploration, rise in government defense budgets, and growing need for environmental radiation testing.On the basis of application, the inorganic scintillators market is segmented into healthcare, homeland security and defense, nuclear power plants, industrial, and other applications (high-energy physics, astrophysics, environmental monitoring, and academic research).In 2016, the healthcare segment is expected to command the largest share of the global inorganic scintillators market, by application.
1
The major factors driving the growth of the laboratory balances and scales market are the technological advancements in laboratory balances and scales; increasing research investments and activities among pharma-biotech companies and CROs; increasingly stringent regulatory framework for product safety in bio-pharmaceutical industries; implementation of stringent food safety guidelines; and emerging markets.The global Laboratory Balances and Scales Market is projected to reach USD 1.6 billion by 2023 from USD 1.3 billion in 2018, at a CAGR of 3.7%.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=166668097The analytical balances segment is expected to account for the largest share of the laboratory balances market, by product type, in 2018Based on product type, the laboratory balances market is segmented into micro & ultra-micro balances, top loading/precision balances, analytical balances, portable/compact balances, moisture analyzers, and other balances.The analytical balances segment is expected to account for the largest share of the laboratory balances and scales market in 2018.The increasing adoption of analytical balances among biopharmaceutical industries, owing to its procedural benefits (such as portability, easy to operate, less weighing time, high durability, low cost, and high precision) is the major factor driving the growth of this market segment.The bench scales segment is expected to witness high growth rate in the laboratory scales market, by product type, in 2018Based on product type, the laboratory scales market is segmented into bench scales, counting scales, compact scales, and other scales.The bench scales segment is expected to witness high growth rate in the laboratory scales market in 2018.The increasing adoption of laboratory scales among bio-pharmaceutical industry due to the procedural benefits offered by these instruments, such as flow-thru design ensures protection from liquids, touchless sensors, minimum stabilization time, ease of handling, and fast measurement time is the major factor driving the growth of this market segment.Pharmaceutical, cosmeceutical, and biotechnology product testing laboratories to account for the largest share of the global balances and scales market during the forecast periodBased on end user, the laboratory balances and scales market is segmented into pharmaceutical, cosmeceutical, and biotechnology product testing laboratories; chemical and material testing laboratories; food and beverage testing laboratories; petroleum product testing laboratories; research laboratories & academic institutes, and other end users.The pharmaceutical, cosmeceutical, and biotechnology product testing laboratories segment is expected to account for the largest share during the forecast period.North America to dominate the laboratory balances and scales market during the forecast periodThe laboratory balances and scales market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World.
1
Growing applications of multimodal imaging systems, technological advancements in diagnostic imaging modalities, availability of funding for research, favorable reimbursement scenario, growing insurance coverage, and increasing R into radiotracers are some of the key factors driving the multimodal imaging market.The report Multimodal Imaging Market  is projected to reach USD 2.9 billion by 2024 from USD 2.3 billion in 2019, at a CAGR of 4.4%.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=3358876The PET/CT segment accounted for the largest share of the multimodal imaging market, by technology, in 2018Based on technology, the multimodal imaging market is broadly segmented into PET/CT systems, PET/MR systems, SPECT/CT systems, OCT/Fundus Imaging systems, and other multimodal imaging systems (tri-modality systems such as SPECT/CT/PET, PET/CT + MR, and IVUS + NIRS systems, among others).The PET/CT systems segment accounted for the largest share of the multimodal imaging market in 2018.This can be attributed to the increasing demand for early and accurate cancer diagnosis, growing clinical evidence for the early detection of Alzheimer’s disease, increasing applications of PET/CT systems in cardiology, favorable reimbursement scenario, and the technological advancements in the field of PET/CT.The oncology segment registered the highest CAGR in the multimodal imaging market in 2018On the basis of application, the multimodal imaging market is segmented into brain & neurology, cardiology, oncology, ophthalmology, and other applications.The oncology segment registered the highest CAGR in 2018.This can be attributed to the expanding use of multimodal imaging systems in oncology diagnosis, increasing demand for the early & accurate diagnosis of cancer, and growing clinical evidence on the use of multimodal imaging in the diagnosis of novel cancer types.North America accounted for the largest share of the multimodal imaging market in 2018The multimodal imaging market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.North America accounted for the largest share of the multimodal imaging market owing to factors such as the increasing availability of radiotracers, technological advancements in diagnostic imaging modalities, high incidence/prevalence of diseases such as breast cancer and colorectal cancer, large number of multimodal imaging procedures performed, growing awareness about the benefits of early diagnosis of diseases, and the rapid adoption of technologically advanced imaging systems.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=3358876Top Key Players:- The major players operating in the multimodal imaging market are GE Healthcare (US), Siemens Healthineers (Germany), Koninklijke Philips N.V. (Netherlands), United Imaging Healthcare Co., Ltd. (China), Canon Medical Systems Corporation (Japan), Mediso Medical Imaging Kft (Hungary), Neusoft Medical Systems Co., Ltd. (China), Spectrum Dynamics Medical (Switzerland), Infraredx, Inc. (Japan), Topcon Corporation (Japan), Carl Zeiss AG (Germany), and Heidelberg Engineering (Germany).
The increasing advancements in the healthcare solutions and production of innovative solutions by manufacturers in the healthcare industry, the medical image analysis software is projected to record significant growth between 2017 and 2022.The report Medical Image Analysis Software Market is expected to reach USD 3.9 billion by 2022, registering a CAGR of 8.2%.Ask for PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=846Market Segmentation: -The adoption of smart technology solutions is gradually transforming the approach and treatment procedures practiced in the healthcare industry.To offer cost-effective and quick medical solutions, software developers are focusing on integrating intelligent features such as cloud-based services that provide improved practice management, allow quick access to patient data saved on mobiles & other wearable devices, and monitor quality measures.As the need for quick access to essential medical information and X-rays for analysis among doctors and surgeons persists, the adoption of integrated software solutions continues to remain high.Integrated software generated the highest revenues in the medical image analysis software market in 2017.With the increasing number of chronic cases, and the growing number of clinical trial and research studies on medical conditions, the demand for medical analysis software solutions continues to remain high in the healthcare industry.Diagnostic centers, hospitals, and research centers are increasingly adopting these software solutions to maintain patient records and analyze the outcome of various treatment procedures.Regional Analysis: -Of the various regions, North America is projected to account for the largest share of the global medical image analysis software market by 2022.A recently published report of the World Health Organization (WHO) stated that by 2020, chronic diseases would account for nearly 73% of all deaths and 60% of the global burden of disease.Moreover, the number of imaging centers is increasing in the region in tandem with the growing geriatric population and the increasing prevalence of various diseases.Request for  Sample Pages: –https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=846Top Key Players: -The increasing presence of new and established players in the medical image analysis software market is likely to intensify the competition.
Factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT are the key factors driving the market growth.The Isothermal Nucleic Acid Amplification Technology/INAAT Market  is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839Market Segmentations:-Based on the product, the INAAT market is segmented into assay, kits, and reagents, and systems.Assay, kits, and reagents segment are expected to account for the largest share of the INAAT industry in 2019, Based on the type, the global market is divided into TMA, LAMP, SDA, HAD, NASBA, and other technologies.Based on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications such as cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis.Based on the end user, the market is divided into hospitals, reference laboratories, academic and research institutes, and other end users.Recent Developments:In 2019, Hologic (US) launched Aptima BV and Aptima CV/TV AssaysIn 2018, Grifols (Spain) ) launched Procleix Babesia assayIn 2018, Tecan Trading AG (Switzerland) acquired Nugen Technologies (US) which helped the company to enhance its next-generation sequencing reagents portfolio.This development helped the company to accelerate its broad genomics strategy.In 2016, Eiken Chemicals (Japan) signed a distribution agreement with HUMAN (Germany), for distribution of loop-mediated isothermal amplification-based tuberculosis and malaria molecular diagnostic systems in the global market (except in Japan, China, Korea, Taiwan, and Thailand).Regional Analysis:-In 2019, North America is expected to account for the largest share of the global INAAT market, followed by Europe.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=839Top Key Players:-The major companies in the global INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US). 
2
The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the healthcare CRM market.The report Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast period.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203Market Segmentation: -Based on end user, the healthcare CRM market is segmented into healthcare providers, the life sciences industry, and healthcare payers.The healthcare providers segment is estimated to account for the largest share of the healthcare CRM market in 2018.This segment is also expected to register the highest CAGR during the forecast period.Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions.Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment.On the basis of component, the healthcare CRM market is segmented into software and services.The services segment is expected to dominate the healthcare CRM market in 2018.
2
The growth of the market is attributed to the increasing geriatric population and subsequent growth in global disease incidence, favorable regulations and government initiatives & investments, the advantages of digital X-ray systems, and technological advancements and product development.The Digital X-ray Market  is expected to reach USD 13.04 billion by 2023 from USD 8.68 billion in 2018, at a CAGR of 8.5%.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1164Market Segmentation: -                                            Based on application, the Digital Radiography Market is segmented into general radiography, dental applications, fluoroscopy, and mammography.In 2018, the general radiography segment is expected to account for the largest share of the digital X-ray market.The growth in this market is mainly driven by the rising prevalence of diseases like tuberculosis, osteoporosis, and CVD; growing aging population; and product launches.By technology, the Digital Radiography Market is segmented into direct radiography and computed radiography.Faxitron Bioptics is a leader in digital specimen radiography.This acquisition enabled Hologic to expand their interventional breast business.In May 2018, Siemens Healthineers partnered with ScreenPoint Medical.This partnership helped Siemens to develop AI-based applications for breast imaging.In April 2018, Konica Minolta, Inc launched KDR Primary Digital Radiography System.In March 2018, Hologic partnered with Philips.
3
The major factors driving the growth of the gene expression analysis market include decreasing cost of sequencing, rising prevalence of cancer, growing application areas of genomics, and the availability of gene expression databases.The global Gene Expression Analysis Market is expected to reach USD 4.9 billion by 2023 from USD 3.2 billion in 2018, at a CAGR of 8.8%.Ask for  PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=156613968Market Segmentation: - On the basis of products and services, the global gene expression analysis market has been segmented into consumables (reagents, DNA chips), Instruments (PCR, NGS, Microarray, others), and services (gene expression profiling services, bioinformatics solutions).The consumables segment is estimated to command the largest share of the market in 2018 and is also projected to register the highest CAGR.The high growth in this segment can be attributed to the growing decreasing sequencing costs leading to increased adoption of sequencing and other gene expression analysis techniques.Based on end user, the market has been segmented into pharmaceutical and biotechnology companies, academic institutes and research centers, and other end users.The pharmaceutical and biotechnology companies’ segment is expected to command the largest share of 54.8% of the market in 2018.The large share and high growth of this segment can be attributed to factors such as high volume of research studies involving gene expression analysis and huge capital for high end analysis instruments and consumables.Regional Analysis: -Geographically, North America is expected to dominate the global gene expression analysis market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period.The high growth in this region can be attributed to domestic manufacturing of sequencing systems, western partnerships to improve healthcare, high R intensity, government focus on cancer and other life science research, and flourishing bioresearch centers.Request for  Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=156613968Top Key Players:-The major players operating in the gene expression analysis market include Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Bio-Rad Laboratories, Inc. (US) are the key players in the gene expression analysis market.
1
The growth of this market can be attributed to the rising preference for continuous manufacturing in the biopharmaceutical industry and the increasing demand for biopharmaceuticals across the globe.The report Hollow Fiber Filtration Market  is projected to reach USD 517.4 million by 2023 from USD 274.7 million in 2018, growing at a CAGR of 13.5%.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267011039Market Segmentation:-On the basis of application, the hollow fiber filtration market is segmented into continuous cell perfusion, harvest and clarification, and concentration and diafiltration.In 2018, continuous cell perfusion is expected to be the largest application segment in the hollow fiber filtration market.The biopharmaceutical industry is actively exploring the potential of continuous manufacturing, with a focus on upstream perfusion cell-culture processes that utilize hollow fiber filters.Due to the advantages of hollow fibers, such as achieving efficient cell separation (with low shear) and allowing robust large-scale manufacturing, they are considered as the most suitable form of membrane filters for TFF and ATF perfusion processes.On the basis of material, the Hollow Fiber Filtration Industry is segmented into polymeric and ceramic materials.In 2018, the polymeric hollow fiber filtration segment is expected to account for a larger share of the market as these filters are widely used in several ultrafiltration and microfiltration applications, including filtration, desalination, and biochemical reactions.Key Market Drivers: -             1 Rising Preference for Continuous Manufacturing             2 Increasing Demand for BiopharmaceuticalsRegional Analysis:-The Asian Pacific is expected to be the fastest-growing regional market for hollow fiber filtration.The high growth in this regional market can be attributed to the expansion of the biomanufacturing sector, increasing government support, developing R infrastructure, and growing outsourcing of bioproduction processes to Asia Pacific countries such as China and India.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=267011039  Top Key Players:-The Hollow Fiber Filtration Industry is consolidated due to the presence of a few major players.
Rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, and the rising demand for external quality assessment support are the key factor driving market growth.The Molecular Quality Controls Market  is expected to grow from USD 132 million in 2018 to USD 237 million by 2024, at a CAGR of 10.2% during the forecast period.Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523Market Segmentation:-Based on product type, the molecular controls market is divided into two major segments—instrument-specific controls and independent controls.The independent controls segment accounted for a larger share of the molecular controls market in 2018.The large share of this segment is attributed to the increasing use of third-party independent quality controls due to their benefits such as longer shelf-life and flexible use across different reagent lots, which help reduce the cost of operations.By analyte type, the molecular controls market is segmented into single-analyte controls and multi-analyte controls.Single-analyte controls dominated the molecular controls market in 2018 primarily due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.Recent Developments:-In 2018, Seracare partnered with AccuRef Diagnostics, a division of Applied StemCell, Inc (US), to market and sell Accuref’s broad portfolio of CRISPR-engineered cell line reference materials.In 2018, Thermo Fisher Scientific partnered with West China Hospital of Sichuan University (China) to establish training centers for standardized pathology quality control, standardized pathologic diagnosticians, and advanced laboratories.In 2017, Bio-Rad launched Amplichek STI—a Multi-analyte Quality ControlIn 2018, Microbiologics launched 8 quality control products such as, Human Papillomavirus (HPV) Control Panel, Vaginal Control Panel, Vaginal Verification Panel, Blood Culture (BCID) Control Panel, Enteric Viral Control Panel and others.Regional Analysis:-North America held the largest share of the market in 2018, Asia Pacific is estimated to grow at the highest CAGR during the forecast period.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=82625523  Top Key Players:-The prominent players in the molecular quality controls market are SeraCare Life Sciences Inc. (US), ZeptoMetrix Corporation (US), Bio-Rad Laboratories Inc. (US), Microbiologics Inc. (US), and Thermo Fisher Scientific (US).
6
The growth of this market is mainly attributed to the shift toward computerized registries from paper-based registries, due to their advantages, is a key driver of market growth.The emergence of the COVID-19 pandemic and the increase in the number of COVID-19 patients globally is also expected to support the demand for patient registry software.The report Patient Registry Software Market  is projected to reach USD 2.4 billion by 2025 from USD 1.2 billion in 2020, at a CAGR of 14.4% from 2020 to 2025.Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144694594Market Segmentation:-Based on the type of registry, the patient registry software market is segmented into product registries, health service registries, and disease registries.The disease registries segment accounted for the largest share of 67.2% of the patient registry software market in 2019.Based on the deployment model, the Patient Registry Software Industry is segmented into on-premise model and cloud-based model.In 2019, on-premise models held 82.6% of the global patient registry software market.The large share of this segment can be attributed to the enhanced control and safety of patient data, and the large number of COVID-19 patients across the globe, which has driven the demand for registries.Based on functionality, the population health management (PHM) segment accounted for the largest market share of 28.9% in 2019.The large share of this segment can be primarily attributed to the implementation of favorable regulations, such as the ACA in the US.Based on the end user, the Patient Registry Software Industry is segmented into private payers; hospitals & medical practices; research centers; pharmaceutical, biotechnology, & medical device companies; and government organizations & TPAs.
3
Growth in this market is driven mainly by high incidence of nerve injuries, the growing prevalence of neurological disorders, and rising government support for neurologic disorder research.The global Nerve Repair and Regeneration Market size is projected to reach USD 9.7 billion by 2025 from USD 6.3 billion in 2020, growing at a CAGR of 9.1% from 2020 to 2025.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=883Market Segmentation: -By product, the nerve repair market is segmented into neurostimulation and neuromodulation devices and biomaterials.The neurostimulation and neuromodulation devices segment is segment is expected to grow at the highest growth rate during the forecast period.The large market share of this segment is driven mainly by rising government expenditure for neurologic disorders, and favorable reimbursement.Based on the neurostimulation and neuromodulation application, the nerve regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications.The internal neurostimulation and neuromodulation segment is estimated to register the highest CAGR during the forecast period.Based on application, the biomaterials market is segmented into direct nerve repair/neurorrhaphy, nerve grafting, and stem cell therapy.In 2019, the direct nerve repair segment accounted for the largest share of the market.Recent Developments: -In 2020, Medtronic received CE approval for InterStim Micro neurostimulator and InterStim SureScan MRI leads — clearing the technologies for commercial sale and clinical use in EuropeIn 2019, Boston Scientific received FDA approval for the Image Ready MRI for its Vercise Gevia Deep Brain Stimulation SystemIn 2020, LivaNova entered into partnership with Verily (US) for evaluation of the effectiveness of Vagus Nerve Stimulation Therapy (VNS Therapy) for difficult-to-treat Depression (DTD)Regional Analysis: -The nerve repair market is segmented into five major regions, namely, Europe, North America, the Asia Pacific, Latin America, and Middle East & Africa.In 2019, North America accounted for the largest share of the nerve repair and regeneration industry, followed by Europe.Request for Sample Pages : - https://www.marketsandmarkets.com/requestsampleNew.asp?id=883  Top Key Players: -Some of the major players operating in the global nerve repair market include Medtronic, PLC.
Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are propelling the growth of the global stem cell therapy market.The Stem Cell Therapy Market is expected to reach USD 161.8 million by 2022, growing at a CAGR of 11.0% during the forecast period.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48Market Segmentation: -On the basis of mode of therapy, the global stem cell therapy market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy.The allogeneic stem cell therapy segment is expected to command the largest share of 95.2% in the global stem cell therapy market in 2017 growing at a CAGR of 11.2% during the forecast period.On the basis of therapeutic application, the global Stem Cell Therapy Industry is segmented into musculoskeletal disorders, wounds and injuries, cardiovascular diseases, surgeries, gastrointestinal diseases, and other applications.The musculoskeletal disorders segment is expected to command the largest share of 61.1% in the global stem cell therapy market in 2017.Furthermore, the CVS diseases segment is expected to grow at the highest CAGR of 13.0% during the forecast period.On the basis of cell source, the global Stem Cell Therapy Industry is divided into adipose derived MSCs, bone marrow derived MSCs, embryonic / cord blood SCs, and other cell sources.The adipose derived MSCs segment was expected to account for the largest share of 59.1% in the global stem cell therapy market in 2017.Market Growth Drivers :- 1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management 2 Development of Advanced Genome-Based Cell Analysis Techniques 3 Increasing Public-Private Investments for the Development of Stem Cell Therapies 4 Development in Infrastructure Related to Stem Cell Banking and ProcessingRegional Analysis:-North America is expected to be the largest regional segment in the global stem cell therapy market in 2017, followed by Asia-Pacific.In addition, the North American stem cell therapy market is expected to be the fastest growing region during the forecast period, growing at a CAGR of 11.5%.Request for Sample Pages  :-https://www.marketsandmarkets.com/requestsampleNew.asp?id=48Key Market Players:-As of 2016, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l.
Factors like growing need for effective and early diagnosis, rising global prevalence of targeted, increasing preference for minimally invasive diagnostic procedures, increasing benefits of CT scans, and technological advancements are driving the growth of the market.The Global CT Scanner Market is projected to reach USD 6.20 Billion by 2022, at a CAGR of 5.4% during the forecast period.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=184364345                Cone beam CT technology segment poised to grow fastest in CT scanner market.On the basis of technology, the CT scanners market is segmented into high-slice CT, mid-slice CT, low-slice CT, and cone beam CT technology.The cone beam CT technology segment is expected to grow faster than the other segments during the forecast period, majorly due to factors like procedural advantages; rising market demand for cosmetic dentistry; and ongoing product development & commercialization across major healthcare markets.Portable CT scanners segment expected to register fastest growth rate in the forecast period.Based on type, the CT scanners market is divided into stationary and portable CT scanners.Portable CT scanners segment is poised to grow faster than the other segment due to increasing number of device installations across major markets, growing application horizons, and the lower switching costs provided by portable CT scanners.North America accounted for the largest share of the CT scanner marketGeographically, the CT scanner market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.North America accounted for the largest share of the market in 2017, which is primarily driven by growth in the aging U.S. population; an increasing public emphasis on minimally invasive & effective disease management strategies; robust reimbursement scenario; increasing adoption of novel applications; and rising public-private investments.Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=184364345The major players in the CT scanner market are Koninklijke Philips N.V. (Netherlands), GE Healthcare (U.S.), Toshiba Corporation (Japan), Siemens AG (Germany), Hitachi Ltd. (Japan), Shimadzu Corporation (Japan), Samsung Electronics Co., Ltd. (South Korea), Neusoft Medical Systems Co., Ltd. (China), Medtronic plc (Ireland), Shenzhen Anke High-tech Co., Ltd. (Hong Kong), Accuray Incorporated (U.S.), PlanMED (Finland), Koning Corporation (U.S.), Carestream Health Inc. (U.S.), and PointNix Co. Ltd (South Korea). 
The growing target patient population and the rising focus on minimally invasive surgical procedures over conventional surgery are the major factors driving the growth of this market.The report Catheters Market is Projected to Reach USD 24.2 Billion by 2025, at a CAGR of 8.7% from 2020 to 2025Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6247803In 2019, the cardiovascular catheters segment accounted for the largest share of the market.On the basis of type, the global catheters market is segmented broadly into cardiovascular, urological, intravenous, neurovascular, and specialty catheters.Cardiovascular catheters commanded the largest share of the catheters market in 2019 and are expected to grow at the highest CAGR during the forecast period.This is primarily attributed to factors such as the high incidence of CVD, the growing geriatric population, and increasing awareness regarding early diagnosis.These factors have resulted in an increase in cardiovascular surgeries, which positively impacts the cardiovascular catheters market.Hospitals to be the largest end users of cathetersBased on end user, the catheters market is segmented into hospitals, long-term care facilities, diagnostic imaging centers, and other end users.In 2019, hospitals were the largest end users of catheters.This segment is expected to grow at the highest CAGR, majorly due to the high volume of target procedures performed in hospitals.
The major factors driving the growth of the surgical retractors market are increasing number of surgical procedures; market availability of specialized and application specific retraction products; continuous expansion of geriatric population; and rising demand for plastic and reconstructive surgeries.The report Surgical Retractor Market is projected to reach USD 2.5 billion by 2023 from USD 1.8 billion in 2018, at a CAGR of 7.2%.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121697708Market Segmentation:- Based on product type, the surgical retractors market is segmented into hand-held retractors, self-retaining retractors, table-mounted retractors, wire retractors, and accessories.The hand-held retractors segment is expected to account for the largest share of the surgical retractors market in 2018.The availability of a wide range of affordable handheld retractors coupled with significant preference of healthcare providers for these products across the world and large number of surgical procedures (especially abdominal and cardiothoracic procedures) conducted across major healthcare markets is the major factor driving the growth of this market segment.Based on applications, the surgical retractors market is segmented into abdominal applications; cardiothoracic applications; orthopedic applications; obstetric and gynecological applications; general surgical applications; head, neck, and spinal applications; aesthetic surgical applications, and other applications.The surgical retractors market for head, neck, and spinal application is expected to witness high growth rate in the during forecast period.Based on end user, the surgical retractors market is segmented into hospitals, clinics, and surgical centers; ambulatory care centers; and maternity and fertility centers.The hospitals, clinics, and surgical center end user segment is expected to account for the largest share during the forecast period.The growing number of surgical procedures across the globe and growth in the number of hospitals, clinics and surgeons providing surgical treatments are the key factors driving the growth of this segment.Regional Analysis: -The surgical retractors market is segmented into four regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World.
Factors such as the growing rate of infertility across the globe, increasing public-private investments in the field of preimplantation genetic testing, rising number of fertility clinics worldwide, technological advancements in the field of genetic analysis, and high risk of chromosomal abnormalities in the fetus with increasing maternal age are driving the growth of this market.The report Preimplantation Genetic Testing Market is projected to reach USD 541.8 Million by 2022 from USD 336.4 Million in 2017, at a CAGR of 10.0%.Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605              The preimplantation genetic screening segment accounted for the largest share of the market in 2016By type, the preimplantation genetic screening segment accounted for the largest share of the market.The large share of this segment can primarily be attributed to the decrease in female fertility (due to rising maternal age), increasing prevalence of genetic disorders in offspring, and benefits of PGS, such as increased chances of healthy pregnancy across all age groups, better implantation rate, reduced risks of miscarriage, reduced IVF cycle time, and comprehensive analysis of all 24 chromosome types.By application, the aneuploidy segment is expected to be the fastest growing segment in the forecast periodThe aneuploidy segment is expected to grow at the fastest CAGR.Growth of this segment can be attributed to the increasing maternal age, rising incidence of aneuploidy disorders, and strategic initiatives by key players to provide technologically advanced PGS products for aneuploidy screening.Aneuploidy screening has been reported to increase the chance of successful embryo implantation, decreases miscarriage rate, and reduce the chance of having a child with a chromosome abnormality).North America dominated the market in 2016Geographically, the preimplantation genetic testing market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World.North America accounted for the largest share of the market in 2016, followed by Europe.Rising number of IVF procedures (with decreasing fertility rates), significant adoption of genomic techniques, ongoing trend of replacing traditional genomic technologies with advanced and innovative genetic techniques (such as FISH and NGS), and increasing private-public funding to develop and commercialize novel PGS & PGD procedures are the key factors that account for the larger share of the preimplantation genetic testing market in North America.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=605As of 2016, the major product manufacturers operating in the global market included Illumina, Inc. (U.S.), CooperSurgical, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abbott Laboratories (U.S.), Natera, Inc. (U.S.), Rubicon Genomics, Inc. (U.S.), Oxford Gene Technology (U.K.), Yikon Genomics (China), and SciGene Corporation (U.S.), among others. 
The key factors driving the growth of this market are the growing prevalence of chronic diseases (such as cancer, diabetes, and cardiovascular diseases), favorable reimbursement scenario in major markets, and technological advancements in injector devices.The Wearable Injectors Market  is projected to reach USD 9.41 billion by 2023 from USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=100771004Market Segmentation:- On the basis of type, the Wearable Injectors Industry is segmented into on-body and off-body injectors.The on-body injectors segment is expected to account for the larger market share in 2018, while the off-body injectors segment is projected to witness the highest growth rate during the forecast period.The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased adoption of off-body injectors.On the basis of therapy, the wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson’s disease, thalassemia, and primary immunodeficiency disorders).In 2018, the immune-oncology segment is expected to account for the largest share of the wearable injectors market.This can be attributed to the high prevalence of cancer across the globe.Recent Developments:-In 2019, Amgen’s Repatha (evolocumab) device options, including the Pre-Filled Syringe and Pushtronex available in the US at a 60% reduced list price.In 2018, Amgen received EU approval for Repatha.In 2018, Medtronic launched MiniMed670G for diabetic patientsIn 2018, Insulet Corporation (US) partnered with Glooko Inc. (US).According to the partnership, Insulet’s Omnipod System user data will be connected with the Glooko+diasend platform in order to review the blood glucose pattern of patients on smartphones.Regional Analysis:-In 2018, North America is expected to account for the largest share of the wearable injectors market, followed by Europe.Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=100771004Top Key Players: -The key players in the global Wearable Injectors Industry are Amgen (US), Medtronic (Ireland), Insulet Corporation (US), Tandem Diabetes Care (US), United Therapeutics Corporation (US), Valeritas (US), and SteadyMed Therapeutics (US).
High prevalence of ophthalmic disorders, rapid growth in geriatric population, technological advancements, increasing regulatory approvals for ophthalmic lasers, rising prevalence of chronic diseases such as diabetes, and increasing initiatives to control visual impairment are expected to drive the growth of the global ophthalmic lasers market in the coming years.The Ophthalmic Lasers Market is expected to reach USD 1,245.4 Million by 2021 from USD 970.2 Million in 2016, at a CAGR of 5.1% from 2016 to 2021.Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=251971654Market Segmentation:-The global ophthalmic lasers market is segmented on the basis of product types, applications, end users, and regions.Based on product type, the ophthalmic lasers market is categorized into femtosecond lasers, excimer lasers, Nd:YAG lasers, diode lasers, and others.The femtosecond lasers segment is expected to command the largest share of the global ophthalmic lasers market, by product type and is projected to grow at the highest CAGR during the forecast period.Based on applications, the ophthalmology lasers market is segmented into refractive error correction, cataract removal, glaucoma treatment, diabetic retinopathy treatment, AMD treatment, and other applications.In 2016, the refractive error correction segment is expected to command the largest share of the global ophthalmic lasers market.Based on end users, the ophthalmic lasers market is segmented into hospitals and clinics & ambulatory surgery centers (ASCs).The hospitals segment is projected to command the largest share of the global ophthalmic lasers market.Key Market Drivers:-             1 High Prevalence of Ophthalmic Disorders             2 Rapid Growth in Geriatric Population             3 Technological Advancements and Increasing Regulatory Approvals for Ophthalmic Lasers             4 Rising Prevalence of Chronic Diseases Such as Diabetes             5 Increasing Initiatives to Control Visual ImpairmentRegional Analysis:-Based on regions, the ophthalmology lasers market is divided into North America, Europe, Asia-Pacific, and the Rest of the World.In 2016, North America is expected to account for the largest share of the global ophthalmic lasers market.Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=251971654Key Market Players:-Alcon Laboratories, Inc. (U.S.), Abbott Medical Optics, Inc. (U.S.), Carl Zeiss Meditec AG (Germany), Bausch & Lomb Incorporated (U.S.), Ellex Medical Lasers Limited (Australia), Topcon Corporation (Japan), Ziemer Ophthalmic Systems AG (Switzerland), IRIDEX Corporation (U.S.), NIDEK Co., Ltd. (Japan), and Lumenis Ltd. (Israel) are some of the key players in the ophthalmic lasers market. 
More

Top